Drug Profile
Tuberculosis vaccine H1IC - AJ Vaccines
Alternative Names: Adjuvanted TB subunit vaccine H1IC - AJ Vaccines; Ag85B-ESAT-6-IC31; H1/IC31 vaccine; H1: IC31; H1ICLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Intercell; Statens Serum Institut
- Developer AJ Vaccines; Statens Serum Institut; Valneva
- Class Adjuvants; Antituberculars; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 27 Sep 2021 No development reported - Phase-II for Tuberculosis (Prevention) in South Africa (IM) (Valneva pipeline, September 2021)
- 27 Sep 2021 No development reported - Phase-II for Tuberculosis (Prevention) in Tanzania (IM) (Valneva pipeline, September 2021)
- 16 Jan 2017 Statens Serum Institut sold its vaccine production business to AJ Vaccines